Introduction {#Sec1}
============

In a select group of patients with type 1 diabetes mellitus (DM) with severe complications, beta-cell replacement by either pancreas or islets of Langerhans transplantation is the treatment of choice, leading to restoration of normoglycemia, reduction of long-term diabetes complications, and improved quality of life \[[@CR1], [@CR2]\]. Results of pancreas transplantation have improved in the last decades by optimization of surgical techniques and immunosuppressive regiments \[[@CR3], [@CR4]\]. Since pancreas transplantation is not a direct life-saving operation, strict donor selection criteria are used when accepting a pancreas \[[@CR2], [@CR5]\]. Despite a growing incidence in type 1 DM worldwide, pancreas transplant numbers in the USA and Eurotransplant region are decreasing, whereas numbers in the UK remain practically stable \[[@CR6]\]. The main reasons for this are the lack of good-quality donor grafts and improvement in DM treatment, even though pancreas transplantation leads to more stable glycated hemoglobin (HbA1c) levels compared with strict insulin regimens \[[@CR7]\], and long-term results of simultaneous pancreas-kidney (SPK) transplantation demonstrate a clear survival benefit as compared with patients who remain on the waiting list \[[@CR8]\]. Forced by donor shortage, nowadays, more extended criteria donors (ECD) are used for transplantation, i.e., donation after brain death donation after brain death donors (DBD) of higher age and BMI, or donation after circulatory death donors (DCD). Most transplanted pancreata originate from DCD Class III (controlled) and less frequently from Class IV (uncontrolled controlled) donors. Maastricht Class I and II (uncontrolled) donors generally are not used for pancreas transplantation \[[@CR9]\]. Clinicians are often reluctant to accept DCD for pancreas transplantation given the higher risk of graft pancreatitis and thrombosis, leading to potentially devastating complications \[[@CR2]\]. The aim of this review is to give an overview on the pathophysiology, risk factors, and outcome in DCD transplantation, to provide tools in selecting suitable pancreas donors and to describe ways to optimize these organs by different preservation methods to safely increase the pancreas donor pool.

Donor Selection {#Sec2}
---------------

It has been generally assumed that the pancreas is much more vulnerable to injury than other abdominal organs \[[@CR10]•\]. Therefore, strict donor selection criteria are used in pancreas transplantation, resulting in much higher discard rates of donor pancreata for transplantation when compared with other abdominal organs \[[@CR5]\]. As a tool to assess suitable pancreas donors, the Pre-Procurement-Pancreas-Suitability-Score (P-PASS) was introduced in 2008 by the Eurotransplant Pancreas Advisory Committee. This scoring system was based on pancreas acceptance rate and includes nine donor parameters: age, body mass index (BMI), duration of intensive care unit (ICU) stay, cardiac arrest, serum sodium, amylase, lipase, and catecholamine dose. A range and point weight for each variable was defined based on clinical expertise and known literature, whereby the variables age and BMI were given twofold higher impact than the other variables. Retrospective analysis of more than 3000 reported pancreas donors identified a P-PASS of 17 as a significant cutoff point (*p* = 0.001) for pancreas acceptance: pancreata from donors with P-PASS \> 17 were three times more likely to be discarded \[[@CR11]\]. Subsequently, Eurotransplant recommends that all donors with a P-PASS \< 17 have to be considered for pancreas donation \[[@CR12]\]. A drawback of the P-PASS is a lack of data on patient and graft survival in the initial report, as it was only based on the pancreas acceptance rate. Also, DCD is not included in the scoring system, while nowadays there is a shift towards increasing numbers of DCD \[[@CR13]\].

In 2010, the pancreas donor risk index (PDRI) was designed using data from the organ procurement and transplantation network (OPTN) with the aim to identify factors associated with pancreas graft survival after 1 year \[[@CR14]\]. This index includes donor factors as well as transplant factors: donor gender, age, race (black/Asian), BMI, height, cause of death, serum creatinine, DCD status, preservation time, and type of transplantation. PDRI was derived from a large data set and provides an index for direct comparison of a potential donor with a "standard donor." This model can help in the decision to accept a pancreas and to compare the results after transplantation.

Several studies have tried to compare and validate the scoring systems in retrospective analyses, usually resulting in conflicting outcomes. In a retrospective study using an Eurotransplant cohort from 2004 to 2014 investigating the predictive value of both indices on pancreas allocation, PDRI was proven more useful than P-PASS to predict pancreas acceptance. However, the authors suggest that potential pancreas donors should never be rejected exclusively based on a high PDRI score and it should be used as a tool to estimate outcome \[[@CR13]\]. The authors also suggest that factors as recipient selection and experience with pancreas transplantation should be included in the consideration to accept a donor pancreas for transplantation.

P-PASS has been evaluated to predict pancreas graft survival in different countries. In a study from Poland, P-PASS was a significant risk factor for 1-year pancreas graft survival; patients with a functioning graft received pancreata from donors with lower P-PASS. A small, but significant, difference in P-PASS was seen; 15.7 versus 16.4 (*p* \< 0.03) \[[@CR15]\]. In another study, a significant association between P-PASS \> 17 and graft failure was only shown within 1 month after transplantation (*p* = 0.025); at 1, 5, and 10 years, this association was no longer demonstrated \[[@CR16]\]. In a study from the Netherlands, no predictive value of P-PASS could be demonstrated \[[@CR17]\].

No predictive value of PDRI on 1- and 5-year graft survival was observed in two studies \[[@CR15], [@CR18]\]. In a large UK cohort, PDRI was significantly associated with 1-year graft survival in simultaneous pancreas-kidneys (SPK) recipients; however, the survival difference between the groups with the highest and lowest risk was only 7% at 5 years after transplantation. One-year graft survival was higher in SPK recipients (88%) compared with pancreas transplant alone (PTA) and pancreas after kidney (PAK) recipients (77%) when they received a pancreas from donors with elevated PDRI (1.57--2.21) \[[@CR19]\]. PDRI was found to be a significant predictor of pancreas graft survival in a Dutch study; however, also good results could be achieved with grafts from high-PDRI donors \[[@CR17]\]. We therefore conclude that the strict use of donor selection tools has limited clinical value and might even lead to refusal of potentially transplantable pancreata. The characteristics of P-PASS and PDRI are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Characteristics of P-PASS and PDRIAim of the scoring systemVariables included in the modelAssociation with pancreas acceptancePrediction of graft survivalDrawbacksP-PASSTo assess suitable pancreas donors, education of involved professionals to increase pancreas transplant ratesDonor age, BMI, ICU stay, cardiac arrest, sodium, amylase, catecholamine usePancreata with P-PASS \> 17 compared with \< 17 are discarded three times more often (*p* \< 0.001) \[[@CR11]\]Weak prediction of organ acceptance (AUC 0.67) \[[@CR13]\]1-year GS associated with P-PASS (15.7 versus 16.4, *p* \< 0.03) \[[@CR15]\]PPAS \> 17 associated with graft failure after 1 month (*p* = 0.025), no association at 1, 5, and 10 years \[[@CR16]\]No predictive value of P-PASS on GS \[[@CR17]\]Median P-PASS of organ donors has increased to 19 \[[@CR13]\]Shift towards more DCD while DCD is not included in P-PASSThe model is based on pancreas acceptance and not outcome after transplantationPDRITo identify factors associated with increased pancreas graft failure, prediction of 1-year graft survivalDonor sex, age, race, BMI, height, cause of death, creatinine, DCD, SPK/PAK transplantation, preservation timeStronger prediction of organ acceptance (AUC 0.79). PDRI is proven more useful than P-PASS to predict pancreas acceptance \[[@CR13]\]No predictive value on 1- and 5-year GS \[[@CR15], [@CR18]\]Significant association with 1-year GS in SPK (HR = 1.52, *p* = 0.009) \[[@CR19]\]PDRI \> 1.5 is associated with decreased GS (HR = 1.792, *p* = 0.018) \[[@CR16]\]PDRI \> 1.24 is associated with reduced GS in multivariate analysis (*p* = 0.002) \[[@CR17]\]Despite strong association of high PDRI donors with decreased GS, good results can be achieved with high risk grafts (PDRI \> 1.24) \[[@CR17]\]PDRI alone cannot be used as a strict criterion for pancreas acceptance*BMI*, body mass index; *ICU*, intensive care unit; *AUC*, area under the curve; *GS*, graft survival; *DCD*, donation after circulatory death; *SPK*, simultaneous pancreas-kidney; *PAK*, pancreas after kidney

Mechanism of Injury in DCD {#Sec3}
--------------------------

In DCD, organs are subjected to a period of warm ischemia, which is thought to have a detrimental effect on organ quality. However, there is no consensus when warm ischemia actually commences and how long an organ can sustain warm ischemia before becoming irreversibly damaged. In the USA, warm ischemia is defined to start after withdrawal of life support therapy (WLST) and ends at the initiation of cold perfusion, while in most European countries, it is defined to start after asystole in the donor. An arterial pressure below 50 mmHg or oxygen saturation below 70% is now considered to be more physiologically relevant than asystole, leading to the increasingly accepted concept of functional warm ischemia \[[@CR10]•\]. WLST is commonly performed at the ICU department, and after declaration of dead and the 5-min "no-touch" period, the donor is taken to the operation room (OR), where a midline laparotomy and cannulation of the aorta are performed. Warm ischemia ends at the start of the cold flush with preservation solution via the aorta. Warm ischemia leads to a quick depletion of intracellular energy sources, such as adenosine triphosphate (ATP), and accumulation of toxic metabolites \[[@CR10]•, [@CR20]\]. In our study on human pancreas preservation, ATP concentration in DCD pancreata was significantly lower compared with DBD pancreata after a median period of 6-h static cold storage (SCS) \[[@CR21]\]. In a canine study on segmental autotransplantation after different periods of warm ischemia (30, 60, 90, and 120 min) followed by 24 h of SCS in University of Wisconsin (UW) solution, a decline in pancreas viability after prolonged warm ischemia was reported \[[@CR22]\]. Pancreas grafts were considered functional when normoglycemia for at least 5 days after transplantation was maintained or by positive evaluation using an intravenous glucose tolerance test 1 week after transplantation. The viability was correlated to the ATP concentrations observed: the tissue concentration of ATP at the end of the preservation period was predictive for post-transplant outcome. The authors demonstrated that pancreata subjected up to 60 min of warm ischemia followed by 24 h of SCS were still functioning after transplantation \[[@CR22]\].

Several procurement protocols are used in order to shorten the length of warm ischemia. In some countries, it is allowed to perform premortem cannulation of the femoral vessels to enable the start of cold preservation directly after declaration of death. Heparin and vasodilatative drugs are also administered just before WLST in some centers \[[@CR23], [@CR24]\]. WLST might take place at the OR instead of the ICU department, resulting in shorter warm ischemia time. These preliminary preparations are unusual in the Eurotransplant region and the UK.

Although by definition the warm ischemic period ends when cold flush has started, biologically, the organ still suffers from lack of oxygen. Therefore, recently, donor organ extraction time is considered to be important as well. This period covers part of the cold ischemia time (CIT); it starts directly after the cold flush in the donor and ends when the organ is retrieved from the body and kept on ice. Earlier studies reported that prolonged kidney extraction time leads to an increase in delayed graft function (DGF) \[[@CR25]\] and prolonged liver extraction time seems to have an independent effect on liver graft outcome after transplantation \[[@CR26]\]. To which extent, whether the duration of pancreas extraction time has an effect on pancreas graft survival has yet to be determined. It is however evident that as all other organs, the pancreas temperature during explantation is far from the desired 4 °C. It has been demonstrated that the core pancreas temperature rises to 16.5 °C during procurement, after an initial decline to 6.8 °C just after the cold flush. In an experimental group, in which additional ice slush was added around the pancreas, the core pancreas temperature remained 9 °C. Results after islet isolation in both groups showed improved outcome in the experimental group regarding to islet equivalent (IEQ), viability, and response to glucose \[[@CR27]\]. The effect of the extraction time or pancreatic temperature on the outcome of solid organ pancreas transplantations is currently unknown, but given the vulnerability of the organ and the impact on other organs, it is likely that extraction time is a relevant risk factor.

In 2015, recommendations from a European expert group concerning DCD pancreas transplantation have been published. Maastricht Class III and IV donors can be reasonably used for vascularized pancreas transplantation, if warm ischemia is limited with a maximum of 30 min. A rapid retrieval technique with perfusion of the abdominal organs should be performed via an aortic cannula. During procurement, ice slush should be added into the lesser sac to ensure topical cooling of the pancreas. Preservation should be performed by static cold storage and preservation time should be minimized.

Outcome of DCD Pancreas Transplantation {#Sec4}
---------------------------------------

Only a few countries worldwide have used DCD for vascularized pancreas transplantation: the USA, Canada, Australia, the UK, the Netherlands, Belgium, Sweden, and Japan. Subsequently, only a few studies reporting outcome after DCD transplantation have been published so far. In 2016, a meta-analysis on all comparative cohort studies reporting the outcome after DCD and DBD pancreas transplantation was published by our group \[[@CR28]••\]. It was concluded that 1-year pancreas graft survival for SPK transplantation did not differ between DBD and DCD. Two of the included studies reported equal long-term results after DCD and DBD pancreas transplants (3- and 10-year patient and graft survival). DCD pancreas recipients were however more prone to develop thrombosis resulting in a higher reoperation rate. Interestingly, this did not lead to a lower patient or graft survival. Different definitions of warm ischemia time (WIT) were used, so no overall median WIT could be calculated. Despite varied lengths of WIT, even up to 110 min, all studies described excellent graft survival rates after 1 year. In 2017, a systematic review on DCD pancreas transplantation was published with equal results regarding to outcome after transplantation. In a subanalysis, WIT and thrombosis rate were compared in studies which used premortem preparations versus studies in which these were not performed. Early femoral cannulation significantly reduced warm ischemia time with approximately 10 min, which is, however, not yet directly associated with graft failure. DCD pancreata were proven to have a significantly higher rate of thrombosis than DBD pancreata. In a subgroup analysis, this was not shown for DCD pancreata procured from donors where premortem heparin administration was used \[[@CR29]••\].

Recently, three papers on the outcome of DCD compared with DBD pancreas transplantation have been published. They all described single-center experiences including small number of patients (DCD groups 10--21 patients and DBD groups 68--596 patients) with a median follow up between 1 and 2.7 years. Two studies reported comparable WIT lengths (30 and 31 min) \[[@CR30], [@CR31]\] while in the third center, WLST was performed at the theater or nearby, leading to short WIT (data not given) \[[@CR32]\]. Median donor age in DCD did not differ from DBD donors in two studies: 32 year \[[@CR30]\] and 21 year \[[@CR32]\], while in the third study, DCD donors were significantly younger than DBD donors: 27 vs. 43 years (*p* = 0.003) \[[@CR31]\]. Excellent graft survival was reported in all studies: 100% after 1 year \[[@CR31], [@CR32]\] and even still 100% after 6 years \[[@CR30]\]. None of the studies reported complete thrombosis leading to graft failure after DCD transplantation. Kopp and colleagues reported an equal PDRI score in both DBD and DCD pancreas donors, however, after eliminating the DCD factor, PDRI in this group was significantly lower: 0.97 versus 1.61 in DCD and DBD respectively. As indicated in this study, good results can be achieved by transplanting DCD pancreata, if careful donor selection is performed \[[@CR31]\]. When it comes to risk factors and predicting outcome after pancreas transplantation, it appears that DCD seems to play a less important role than initially thought and could therefore be considered to be a justified source of donor pancreata.

Pancreas Preservation {#Sec5}
---------------------

Nowadays, protocols for DCD pancreas preservation are quite similar to DBD protocols and are based on the principle of reducing cellular metabolism by lowering the temperature of the organ by SCS. With every 10 °C drop in temperature, cellular metabolism decreases two- to threefold, thereby leading to reduced oxygen and ATP use and reduction of ischemic injury \[[@CR33]\]. However, at 4 °C, 10% of metabolism is still maintained, resulting in depletion of ATP levels in the absence of oxygen \[[@CR34]\]. Together with the rapid decline of energy sources during the warm ischemic period in DCD organs, this period can further lead to a cellular "oxygen debt," which results in the production of radical oxygen species and increased injury during reperfusion \[[@CR20], [@CR35]\].

Preservation solutions have been developed to counteract ischemic injury \[[@CR36]\]. These act mostly by reducing cellular swelling and maintaining pH balance and in some solutions oxygen-free-radical scavengers and precursors for ATP are added. Studies have shown that preservation with either UW, Histidine-Tryptophan-Ketoglutarate (HTK), Celsior and Institute Georgez Lopez-1 (IGL-1) did not show superiority over another \[[@CR37]\]. Currently, no studies have been performed that analyzed the effect of different preservation solutions on DCD pancreas transplants. Given the differences in injury during DBD and DCD procedures, it is likely to accept that different treatments for these organs might be necessary \[[@CR36]\]. Multiple techniques have been developed and tested in order to reduce ischemia-reperfusion injury after transplantation. These techniques are most of all focused on maintaining cellular ATP by delivery of high oxygen concentrations to the tissue. The most explored techniques for pancreas preservation will be explained further.

### Two-Layer Method {#Sec6}

In 1988, the two-layer method (TLM) was developed by a Japanese group with the intention to improve pancreas viability during preservation for islet isolation. This technique involves the addition of perfluorocarbon (PFC) to the preservation solution, in order to combine the characteristics of the preservation solution and PFC together to prevent injury and supply oxygen during preservation. PFC is an inert solution with a high capacity for dissolving oxygen \[[@CR34]\]. By addition of PFC to a preservation fluid, two layers are formed with PFC at the bottom and the preservation solution on top. The organ is placed in the solution which is presaturated with oxygen or continuously oxygenated during preservation. Oxygen is delivered to the pancreas by passive diffusion, with the intention to achieve ATP production in the presence of precursors in the preservation solution \[[@CR36], [@CR37]\]. Experimental studies in small animals showed promising results of TLM regarding to ATP levels when compared with SCS \[[@CR38]\]. The ability of oxygen to penetrate deep in the tissue of large animals and humans is however questioned. In porcine pancreata preserved by the TLM, ATP levels were nearly undetectable and indistinguishable from those preserved by SCS alone \[[@CR39]\]. In a large retrospective study from Sweden, the outcome of 200 islet isolations from human pancreata was analyzed, from which 103 pancreata were preserved by TLM and 97 pancreata by SCS. No differences with regard to islet yield, purity, or dynamic glucose stimulation after islet isolation was demonstrated. Islet post-transplant function in recipients was also equal in both groups. Subgroup analysis showed that TLM did not improve outcome either after prolonged CIT or in elderly donors (\> 60 years of age) \[[@CR40]\]. Recently, no studies on TLM of the pancreas have been published and as far as we know, TLM is not routinely used for pancreas preservation.

### Persufflation {#Sec7}

In organ persufflation, humidified and filtered oxygen is bubbled directly to an organ via its vasculature. Oxygen persufflation can either be performed anterograde (through the arteries) or retrograde (through the portal vein). The technique was first discovered coincidentally in 1902 when compressed oxygen instead of blood was perfused through a feline heart, leading to continuation of heart contractility \[[@CR41]\]. In the last decades, the beneficial effects of this technique have been analyzed in experimental settings in the heart, kidneys, and livers. It has been shown that with this relatively simple technique, oxygen could be delivered to organs during cold storage, whereby ATP levels could be replenished and maintained with associated reduction of oxidative stress and lipid peroxidation \[[@CR42]--[@CR45]\]. Research concerning pancreas persufflation has been focused on pancreas preservation for islet transplantation. Scott et al. reported in their study on anterograde persufflation of DBD human and DCD porcine pancreata via the splenic artery and celiac trunk that oxygen was uniformly distributed throughout the organ and ATP concentration was restored \[[@CR38]\]. Persufflation dramatically improved tissue health as shown by distended capillaries and significantly less autolysis and cell death when compared with TLM \[[@CR39]\]. In a rat model, portal venous persufflation of the pancreas has shown to be superior to SCS and HMP regarding outcome of islet isolation \[[@CR46]\]. In a recent study on human pancreata, a lowered expression of inflammatory genes in isolated islets after persufflation compared with SCS was reported. Preservation time could be extended with persufflation without additional loss of islet function or viability \[[@CR47]\]. This technique is promising for pancreas preservation, as it allows the delivery of oxygen properly to the pancreatic tissue, without major complications. However, no research has yet been performed on its use in pancreas preservation for solid organ transplantation.

### Machine Perfusion {#Sec8}

Hypothermic machine perfusion (HMP) is a technique which enables continuous circulation of the microvasculature with cold preservation solution, removing toxic metabolites and supporting ATP synthesis by delivery of oxygen and adenosine \[[@CR36]\]. HMP has been evaluated in donor organ preservation for different reasons; to improve the quality of marginal donor organs, to extend the preservation time, and to test graft viability. Previous clinical studies in kidneys showed especially beneficial effects of HMP on graft function after DCD or ECD kidney transplantation \[[@CR48]\], and this technique is nowadays standard of care in some countries, among which is the Netherlands. In experimental and clinical studies on human DCD livers, excellent results were reported after oxygenated HMP with a restoration of ATP and improved hepatobiliary function \[[@CR49]\] and a 100% graft survival 6 months after transplantation \[[@CR20]\].

Early studies on HMP of canine pancreata concluded that pancreas storage time could be extended up to 24 h, while retaining viability \[[@CR50]\] and function of isolated islets after autotransplantation in dogs \[[@CR51]\]. Another study reported that tissue flow rate during HMP was a predictable index of pancreatic graft viability \[[@CR52]\]. There has always been a hesitation to HMP of the pancreas, because it is a low-flow organ with a delicate vasculature and HMP is associated with edema and congestion with the risk of thrombosis \[[@CR36], [@CR53]\]. Because HMP of the pancreas is relatively complex and results of SCS have improved after development of dedicated perfusion solution, HMP fell out of favor. Lately, however, there is renewed interest in HMP of the pancreas, mainly because the lack of good-quality pancreas donors forces the search to improve the quality of marginal donor pancreata. During the last 15 years, few studies on HMP of the pancreas have been reported. Most of them involved animal pancreata and focused on pancreas preservation for islet isolation. Twenty-four hours of HMP of porcine pancreata led to moderate edema without loss of function of the isolated islets. The edema seemed to aid in enzymatic digestion, leading to a higher islet yield and purity of isolated islets compared with 24 h of SCS \[[@CR54], [@CR55]\]. In a split lobe porcine model, the results of islet transplantation in diabetic mice after 24-h HMP were analyzed. All mice receiving islets from HMP preserved pancreata showed recovery in diabetes and high viability as measured by oxygen consumption \[[@CR56]\]. A protective effect on graft histopathology by 6-h HMP was reported in DCD porcine pancreata \[[@CR57]\].

In the first study on human pancreata, four human donor pancreata were perfused for 4 h by HMP after 13 h of SCS, resulting in an adequate amount of islets that could be isolated with excellent in vitro viability \[[@CR58]\]. In a recent study performed by our team, 20 human pancreata were included, from which 10 (5 DCD and 5 DBD) were subjected to 6-h HMP and 10 (5 DCD and 5 DBD) to 6-h of additional SCS after a median period of 6-h SCS. Oxygenated HMP with 25 mmHg was performed via the splenic and mesenteric artery separately. Uniform perfusion of the pancreata as shown by fluorescence microscopy was obtained and perfusion flow increased during the first minutes of HMP before it stabilized. ATP concentration increased significantly after HMP in both DCD and DBD organs with a respectively 6.8-fold and 2.6-fold increase. Also, ATP concentration of DCD pancreata was significantly lower at the start of HMP (8.4 in DCD and 48.2 μmol/g protein in DBD), which corrected after HMP to equal ATP concentrations (100.5 in DCD and 109.3 μmol/g protein in DBD). HMP did not induce cellular injury or edema. In two DCD pancreata, islet isolation was performed with good viability and in vitro function \[[@CR21]\]. Another study demonstrated that 24 h of HMP with a perfusion pressure of 25 mmHg did not lead to macroscopic edema on human pancreata as conformed by histological analysis. After 12 h of HMP, insulin, glucagon, and somatostatin staining were normal \[[@CR35]\]. This evidence suggests that HMP of the human pancreas is a safe preservation method regarding tissue injury and edema formation and replenishment of ATP can be achieved. However, the main limitation of these studies is the lack of a post-transplant evaluation reperfusion model in a normothermic environment.

Normothermic machine perfusion (NMP) can be used to improve organ quality during preservation and facilitate the administration of drugs, and it allows viability testing in a physiological environment prior to transplantation \[[@CR59]\]. In experimental settings, it has been successfully used for viability testing in human donor livers \[[@CR60]\] and kidneys \[[@CR61]\]. Viability assessment of porcine pancreata was performed using NMP, to examine the effect of 5-h HMP compared with SCS alone after a prolonged period of 24-h CIT \[[@CR53]\]. During HMP, perfusion flow was stable and the grafts experienced a weight gain of 15.3--27.6%. Perfusion flow indices (PFI) remained stable during normothermic reperfusion in the pancreata that were attributed to HMP, whereas the SCS-only pancreata showed declined PFI during reperfusion. In the second part of the study, three discarded human pancreata were perfused by HMP after prolonged period of CIT (up to 56 h). Stable PFI was shown with only mild weight gain (3.9% and 14.7%). Functional assessment during NMP demonstrated beta-cell viability in these grafts, even after prolonged period of SCS \[[@CR53]\]. In a study on five discarded human pancreata, 1--2 h of NMP was performed for viability assessment after a median CIT of 13 h. One pancreas with a CIT of over 30 h was excluded from the analysis, given the macroscopically ischemic appearance of the duodenum and therefore poor comparability to the other organs according to the authors. In the included four pancreas grafts, stable mean arterial flow was maintained during NMP, and insulin secretion was observed in all pancreata although tissue edema did occur in all grafts \[[@CR59]\]. In a study evaluating NMP as a preservation, 2-h NMP was performed in four DCD porcine pancreata after a short WIT (8.3 ± 6.6 min) and CIT (34 ± 7.8 min). All pancreata became moderately to severely edematous, congested, and hemorrhagic during NMP. Extensive hemolysis occurred and the pancreas looked grossly ischemic at the end of preservation \[[@CR62]\]. As these studies give an insight in the possibility of NMP for assessing pancreas viability, the technique should be further optimized to avoid hemolysis and edema.

Conclusion {#Sec9}
==========

Despite a growing incidence in type 1 DM, pancreas transplantation rates are declining worldwide. As beta-cell replacement is the best therapeutic option for these patients, better assessment of possible pancreas donors is needed to expand the donor pool without compromising the outcome. This overview shows that excellent results can be achieved with DCD pancreas transplantation, when other detrimental donor characteristics are kept to a minimum. Donor selection tools are developed in order to assess potential pancreas donors. PDRI did show to have a predictive value in outcome; however, conflicting cutoff points have been found in different studies. PDRI can be used as a tool to estimate the risk of a certain donor pancreas; nevertheless, other transplant and recipient factors should be kept in consideration. DCD should not be the sole reason to decline a pancreas for transplantation, though accumulation of risk factors in these donors should be avoided. Hypothermic oxygenated machine perfusion seems a promising preservation method for these organs, as it safely replenishes ATP concentrations.
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